Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Kiadis Pharma Augustus 2018
Volgen
Molmed wordt niet overgenomen, dus waarom Kiadis wel...???
Biobert schreef op 30 augustus 2018 12:41 :
[...]
Ik denk aan Novo Nordisk als overnemende partij
En wat voor een bedrag denk je dan aan, 3 a 4 miljard
DeZwarteRidder schreef op 30 augustus 2018 15:30 :
Molmed wordt niet overgenomen, dus waarom Kiadis wel...???
Gezien het fundamentele verschil in de behandeling; ATIR richt zich op het voorkomen van GVHD, Zalmoxis op het behandelen in GVHD zich voordoet. Bovendien wordt aangenomen dat ATIR een goedkopere behandeling is in directe zin (de behandeling zelf) en in indirecte zin (het niet hoeven behandelen van GVHD). En omdat Kiadis Maarten van der Weijden als ambassadeur heeft... :)
BlijvenHopen schreef op 30 augustus 2018 14:26 :
Waarom stapt Robbert van Heekeren eigenlijk op? Zo vlak voor de belangrijkste tijd in de geschiedenis van Kiadis Phrama (of toch niet?). Is hij het niet eens met het nieuw te voeren (amerikaanse) beleid? En gaat er nog heeel veel geld opgehaald worden (lees aandelen uitgegeven worden)…..
Nou, denk je dat dit opstappen is. Niet dat hij eruit moet, maar op een gegeven moment past een ander profiel beter bij de huidige situatie en toekomst.
kiadis.com/news-and-events/events/ kiadis is weer aanwezig in September op Goldman Sachs 8th Annual Biotech Symposium Oppenheimer Fall Summit focused on Specialty Pharma and Rare Disease KBC Securities 6th Biotech and Healthcare Conference
CytoDyn receives ODD for PRO 140 for prevention of GvHD Stock MarketsOct 05, 2017 08:42AM ET CytoDyn (OTCQB:CYDY) announces that the FDA has granted Orphan Drug designation to PRO 140 for the prevention of graft versus host disease (GvHD). Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved. PRO 140 is a humanized IgG4 monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T cells.
DeZwarteRidder schreef op 30 augustus 2018 20:54 :
CytoDyn receives ODD for PRO 140 for prevention of GvHD Stock MarketsOct 05, 2017 08:42AM ET CytoDyn (OTCQB:CYDY) announces that the FDA has granted Orphan Drug designation to PRO 140 for the prevention of graft versus host disease (GvHD).
Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.
PRO 140 is a humanized IgG4 monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T cells.
www.cytodyn.com/new-developments We have initiated our first clinical trial with PRO 140 in an immunological indication – a Phase 2 clinical trial with PRO 140 for Graft versus Host Disease (GvHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. GvHD represents an unmet medical need, with patients who contract GvHD during stem cell transplant having a significantly decreased 1-year survival rate with relapsed GvHD as the leading cause of death. PRO 140 is also being investigated in animal models of cancer progression and autoimmunity with positive results. Our animal studies in GvHD have been submitted for publication in peer-reviewed journals. Heb het even doorgelezen maar ik denk dat Kiadis een heel stuk verder is in Europa. Voor de USA moet ik er even verder induiken....maar nu even niet. Wat me wel opvalt is dat je bericht van 5 oktober 2017 is.
14,1 miljoen verlies........
Kiadis Pharma announces Financial Results for the six months ended June 30, 2018 and Company update Amsterdam, The Netherlands, August 31, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces its unaudited interim Financial Results for the six months ended June 30, 2018, which have been prepared in accordance with IAS 34 as adopted by the European Union. Arthur Lahr, CEO of Kiadis Pharma, commented: “We have made tremendous progress in the last six months: ATIR101 is now very close to potential CHMP opinion in 2018, we are on track with our Phase 3 trial, and obtained further confirmatory data from our Phase 2 trials. To allow us to ramp up our Phase 3 trial and prepare for commercialization in the EU we also raised substantial equity and debt facilities that extended our cash runway into the third quarter of 2019, and, upon positive CHMP opinion, potentially into the first quarter of 2020. We have also significantly strengthened our organization in medical, operations, commercial and finance functions. Kiadis is in great shape and well positioned to deliver on the promise of ATIR101.” Operating highlights – ATIR101 (including post reporting period) European marketing authorization application for ATIR101: Responses to the Day 120 List of Questions submitted in March 2018; Day 180 List of Issues received in May 2018 and responses submitted in August 2018; On track to obtain CHMP opinion from the European Medicines Agency in the fourth quarter of 2018. Phase 3 trial CR-AIR-009, comparing ATIR101 against the post-transplant cyclophosphamide (PTCy) or ‘Baltimore’ protocol: Progress in line with internal plans: 14 clinical sites are currently open for recruitment, 16 patients have been enrolled; Protocol amendment submitted to regulatory authorities: number of patients increased to 250 to further increase power [80% power to detect 16% Graft-versus-host-disease-free and Relapse-Free Survival (GRFS) difference]; interim analysis to occur after 2/3 of GRFS events to increase chance of positive read out, now expected in the second half of 2020; conditioning regimens harmonized between the two treatment arms to reduce heterogeneity. Phase 2 trial CR-AIR-008 (‘008’): The last patient received a single dose of ATIR101 in January 2018. Pooled analysis: Further analysis of 1-year Phase 2 pooled data [Intention-To-Treat (ITT), 37 patients] from studies CR-AIR-007 and single dose CR-AIR-008 shows GRFS 53% [95% confidence interval (CI), 39%-72%]; Overall Survival (OS) 58% (95% CI, 44%-77%), in line with Phase 2 CR-AIR-007 trial. For the PTCy/Baltimore protocol, single site data from Johns Hopkins (McCurdy et al. 2017) and Atlanta (Solh et al, 2016) show a disease-risk index (DRI) normalized 1-year GRFS value of 40% and 30%, respectively. Operating highlights – Organization (including post reporting period) Robbert van Heekeren resigned as Chief Financial Officer and as member of the Management Board. Scott A. Holmes appointed as new Chief Financial Officer. Organization strengthened across all functions, comprises 73 employees, up from 51 a year ago. Key new appointments include head of Medical US (former Iovance/ Dendreon), head of Medical EU (former Genzyme/ AstraZeneca), head of market access EU (former Genzyme/ Novo Nordisk), head of pharmacovigilance (former Astellas), head of facilities (former Merck/ Douwe Egberts). Otto Schwarz, former Chief Operating Officer of Actelion and Mr. Subhanu Saxena, former Chief Executive Officer of Cipla and former member of the senior executive team of Novartis, were appointed as Supervisory Board members of the Company at the Annual General Meeting of shareholders in June 2018. Mr. Stuart Chapman resigned from the Supervisory Board following the shareholders’ meeting. Financial highlights (including post reporting period) FINANCIAL SUMMARY For the six months ended (Amounts in EUR million, except per share data) June 30, 2018 June 30, 2017 Change Total revenue and other income – – – Total operating expenses (11.1) (8.2) (2.9) Research and development (7.7) (5.9) (1.8) General and administrative (3.4) (2.3) (1.1) Operating result (11.1) (8.2) (2.9) Net financial result (3.0) (0.4) (2.6) Net result (14.1) (8.5) (5.6) Net operating cash flow (10.6) (7.6) (3.0) Cash position at end of period 41.7 10.7 31.0 Equity 25.3 3.5 21.8 Earnings per share before dilution (EUR) (0.74) (0.61) (0.13) In the first six months of 2018, the Company did not generate any revenues. Total operating expenses increased by EUR2.9 million from EUR8.2 million in the first six months of 2017 to EUR11.1 million in the same period of 2018. This increase was primarily caused by a further expansion of the workforce in all areas of the organization, the move to a larger building which includes a commercial manufacturing facility, laboratories and office space, and consultancy expenses for business development and market access. In the first six months of 2018, net financial result came in at EUR3.0 million compared to EUR0.4 million for the same period of 2017. Higher finance costs were mainly the result of higher interest expenses on loans and borrowings, and a net foreign exchange loss in the first six months of 2018 compared to a net foreign exchange gain in 2017. The net loss for the six months ended June 30, 2018 came at a level of EUR14.1 million compared to a loss of EUR8.5 million for the six months ended June 30, 2017. Operating expenses and net result for the first six months of 2018 were in line with management expectations. The Company ended the first six months of 2018 with EUR41.7 million in cash and cash equivalents. In March 2018, the Company issued 2.6 million shares and raised EUR23.4 million in gross proceeds. On July 31, 2018, the Company received a new debt facility from Kreos Capital V (UK) Ltd providing the Company with up to EUR20 million of additional financing.
Verlies Kiadis Pharma loopt op Gepubliceerd op 31 aug 2018 om 07:27 AMSTERDAM (AFN) - Kiadis Pharma heeft zijn verlies in het afgelopen halfjaar zien oplopen ten opzichte van een jaar eerder. Het in Amsterdam genoteerde farmaceutisch oncologiebedrijf maakte onder meer kosten voor het verder op peil brengen van het personeelsbestand. Verder kampte Kiadis met hoger rentekosten en negatieve wisselkoerseffecten. Het bedrijf, dat nog geen omzet draait, sprak zelf van operationele uitgaven conform de verwachtingen. Het nettoverlies kwam uiteindelijk uit op 14,1 miljoen euro, tegenover een tekort van 8,5 miljoen een jaar eerder. De kaspositie werd aanzienlijk verbeterd van 10,7 miljoen vorig jaar naar 41,7 miljoen euro eind juni, door de uitgifte van nieuwe aandelen en een nieuwe financiering. Kiadis heeft nu naar eigen zeggen voldoende middelen in kas om het zeker tot in het derde kwartaal van volgend jaar uit te zingen. Het bedrijf zegt verder goede vooruitgang te hebben geboekt met het uiteindelijk op de markt brengen van zijn belangrijkste middel ATIR101.
Arthur Lahr, CEO of Kiadis Pharma, commented: “We have made tremendous progress in the last six months: ATIR101 is now very close to potential CHMP opinion in 2018, we are on track with our Phase 3 trial, and obtained further confirmatory data from our Phase 2 trials. To allow us to ramp up our Phase 3 trial and prepare for commercialization in the EU we also raised substantial equity and debt facilities that extended our cash runway into the third quarter of 2019, and, upon positive CHMP opinion, potentially into the first quarter of 2020. We have also significantly strengthened our organization in medical, operations, commercial and finance functions. Kiadis is in great shape and well positioned to deliver on the promise of ATIR101.” Dit stukje vind ik belangrijker dan de cashburn.
BlijvenHopen schreef op 31 augustus 2018 07:20 :
14,1 miljoen verlies........
Ze hebben toch geld zat.....!! Ze kunnen best een dividenduitkering doen...!!
Lahr is overtuigd van de enorme progressie die de afgelopen 6 maanden gemaakt is en is erg positief over de verwachte goedkeuring. Organisatie staat nu helemaal klaar om de goedkeuring te gaan ontvangen! List of issues na de beantwoording van april ontvangen door Kiadis in de maand Mei en deze issues zijn deze maand weer beantwoord door Kiadis. Laat die goedkeuring binnen 7 weken nu maar komen. Voor de rest, financials, geen inkomsten en wel kosten. Niets nieuws onder de zon. Benieuwd of de markt vanaf 9 uur nog een mening heeft over de update.
Het enige nieuws waar ik op zat te wachten:Day 180 List of Issues received in May 2018 and responses submitted in August 2018 Goed nieuws, de goedkeuringsprocedure is weer opgestart na de Dag 180 stop.
Vooralsnog laat het orderboek nog weinig reactie zien.
Sjonnie2 schreef op 31 augustus 2018 07:37 :
Het enige nieuws waar ik op zat te wachten:
Day 180 List of Issues received in May 2018 and responses submitted in August 2018 Goed nieuws, de goedkeuringsprocedure is weer opgestart na de Dag 180 stop.
Ze liggen goed op schema en de goedkeuring ligt nu binnen handbereik. een hogere cashburn is evident,hoe verder in process Hoe hoger deze is.
er worden nu 450 stukken in de laat gelegd op 9,35......het orderboek begint wederom weer rare patronen te tonen, de contollers worden wakker.
Windkracht schreef op 31 augustus 2018 07:58 :
er worden nu 450 stukken in de laat gelegd op 9,35......het orderboek begint wederom weer rare patronen te tonen, de contollers worden wakker.
Geen weldenkend mens verkoopt nu zo laag, manupilatie mijn idee. Er zijn ook beleggers die amper weten waar ze in beleggen en die lezen grotere verlies... maar goed ik hou ze vast wat voor rare koerssprongen er vandaag ook zullen zijn.
Windkracht schreef op 31 augustus 2018 07:58 :
er worden nu 450 stukken in de laat gelegd op 9,35......het orderboek begint wederom weer rare patronen te tonen, de contollers worden wakker.
Er zijn heel veel teleurgestelde aandeelhouders.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
874,02
0,00%
EUR/USD
1,0709
+0,11%
FTSE 100
8.040,38
0,00%
Germany40^
18.086,70
-0,01%
Gold spot
2.317,62
+0,07%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers